Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.49 |
| ▸ | TEK | Q02763 | 6/20 | 0.39 |
| ▸ | KDR | P35968 | 5/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25355685 | 0.92 | HDAC6 (0.49) | HDAC6HDAC1TEKKDR | |
| SCHEMBL25355239 | 0.89 | HDAC1 (0.44) | HDAC6HDAC1 | |
| SCHEMBL24216393 | 0.87 | HDAC6 (0.51) | HDAC6HDAC1TEKKDREPHB4 | |
| SCHEMBL31535166 | 0.87 | HDAC6 (0.51) | HDAC6HDAC1TEKKDREPHB4 | |
| SCHEMBL25355437 | 0.87 | HDAC6 (0.52) | HDAC6HDAC1TEKKDREPHB4 | |
| SCHEMBL25349768 | 0.87 | HDAC1 (0.51) | HDAC6HDAC1TEKKDREPHB4 | |
| SCHEMBL25351125 | 0.87 | HDAC1 (0.52) | HDAC6HDAC1DPP4DPP8DPP9 | |
| SCHEMBL24216687 | 0.86 | HDAC6 (0.51) | HDAC6HDAC1TEKKDREPHB4 | |
| SCHEMBL30409410 | 0.86 | HDAC6 (0.51) | HDAC6HDAC1TEKKDREPHB4 | |
| SCHEMBL25351724 | 0.85 | HDAC6 (0.53) | HDAC6HDAC1TEKKDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885TEK 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.